Limits...
The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study.

Ezekowitz JA, Becher H, Belenkie I, Clark AM, Duff HJ, Friedrich MG, Haykowsky MJ, Howlett JG, Kassiri Z, Kaul P, Kim DH, Knudtson ML, Light PE, Lopaschuk GD, McAlister FA, Noga ML, Oudit GY, Paterson DI, Quan H, Schulz R, Thompson RB, Weeks SG, Anderson TJ, Dyck JR - BMC Cardiovasc Disord (2014)

Bottom Line: Patients will have sequential testing including quality of life and clinical outcomes over 12 months.Clinical outcomes of interest include death, hospitalization, emergency department visits, physician resource use and/or heart transplant.Patients will be followed for a total of 5 years.

View Article: PubMed Central - HTML - PubMed

Affiliation: Mazankowski Alberta Heart Institute, 2C2 WMC, 8440-112 Street, Edmonton, AB, Canada. jae2@ualberta.ca.

ABSTRACT

Background: Nationally, symptomatic heart failure affects 1.5-2% of Canadians, incurs $3 billion in hospital costs annually and the global burden is expected to double in the next 1-2 decades. The current one-year mortality rate after diagnosis of heart failure remains high at >25%. Consequently, new therapeutic strategies need to be developed for this debilitating condition.

Methods/design: The objective of the Alberta HEART program (http://albertaheartresearch.ca) is to develop novel diagnostic, therapeutic and prognostic approaches to patients with heart failure with preserved ejection fraction. We hypothesize that novel imaging techniques and biomarkers will aid in describing heart failure with preserved ejection fraction. Furthermore, the development of new diagnostic criteria will allow us to: 1) better define risk factors associated with heart failure with preserved ejection fraction; 2) elucidate clinical, cellular and molecular mechanisms involved with the development and progression of heart failure with preserved ejection fraction; 3) design and test new therapeutic strategies for patients with heart failure with preserved ejection fraction. Additionally, Alberta HEART provides training and education for enhancing translational medicine, knowledge translation and clinical practice in heart failure. This is a prospective observational cohort study of patients with, or at risk for, heart failure. Patients will have sequential testing including quality of life and clinical outcomes over 12 months. After that time, study participants will be passively followed via linkage to external administrative databases. Clinical outcomes of interest include death, hospitalization, emergency department visits, physician resource use and/or heart transplant. Patients will be followed for a total of 5 years.

Discussion: Alberta HEART has the primary objective to define new diagnostic criteria for patients with heart failure with preserved ejection fraction. New criteria will allow for targeted therapies, diagnostic tests and further understanding of the patients, both at-risk for and with heart failure.

Trial registration: ClinicalTrials.gov NCT02052804.

Show MeSH

Related in: MedlinePlus

Alberta HEART adjudication process.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4222863&req=5

Figure 2: Alberta HEART adjudication process.

Mentions: Each of the three definitions will be applied to the cohort in order to evaluate the sensitivity, specificity, diagnostic accuracy, positive predictive value and negative predictive value using the diagnostic testing model based on Bossuyt et al.[20] and Sackett and Haynes[21] and the reporting methods endorsed by STARD[22] and QUADAS-2[23]. A reference standard for HF-PEF is currently absent. Therefore, we have chosen to use a consensus panel approach using a panel of adjudicators blinded to the group of original recruitment (FigureĀ 2).


The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study.

Ezekowitz JA, Becher H, Belenkie I, Clark AM, Duff HJ, Friedrich MG, Haykowsky MJ, Howlett JG, Kassiri Z, Kaul P, Kim DH, Knudtson ML, Light PE, Lopaschuk GD, McAlister FA, Noga ML, Oudit GY, Paterson DI, Quan H, Schulz R, Thompson RB, Weeks SG, Anderson TJ, Dyck JR - BMC Cardiovasc Disord (2014)

Alberta HEART adjudication process.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4222863&req=5

Figure 2: Alberta HEART adjudication process.
Mentions: Each of the three definitions will be applied to the cohort in order to evaluate the sensitivity, specificity, diagnostic accuracy, positive predictive value and negative predictive value using the diagnostic testing model based on Bossuyt et al.[20] and Sackett and Haynes[21] and the reporting methods endorsed by STARD[22] and QUADAS-2[23]. A reference standard for HF-PEF is currently absent. Therefore, we have chosen to use a consensus panel approach using a panel of adjudicators blinded to the group of original recruitment (FigureĀ 2).

Bottom Line: Patients will have sequential testing including quality of life and clinical outcomes over 12 months.Clinical outcomes of interest include death, hospitalization, emergency department visits, physician resource use and/or heart transplant.Patients will be followed for a total of 5 years.

View Article: PubMed Central - HTML - PubMed

Affiliation: Mazankowski Alberta Heart Institute, 2C2 WMC, 8440-112 Street, Edmonton, AB, Canada. jae2@ualberta.ca.

ABSTRACT

Background: Nationally, symptomatic heart failure affects 1.5-2% of Canadians, incurs $3 billion in hospital costs annually and the global burden is expected to double in the next 1-2 decades. The current one-year mortality rate after diagnosis of heart failure remains high at >25%. Consequently, new therapeutic strategies need to be developed for this debilitating condition.

Methods/design: The objective of the Alberta HEART program (http://albertaheartresearch.ca) is to develop novel diagnostic, therapeutic and prognostic approaches to patients with heart failure with preserved ejection fraction. We hypothesize that novel imaging techniques and biomarkers will aid in describing heart failure with preserved ejection fraction. Furthermore, the development of new diagnostic criteria will allow us to: 1) better define risk factors associated with heart failure with preserved ejection fraction; 2) elucidate clinical, cellular and molecular mechanisms involved with the development and progression of heart failure with preserved ejection fraction; 3) design and test new therapeutic strategies for patients with heart failure with preserved ejection fraction. Additionally, Alberta HEART provides training and education for enhancing translational medicine, knowledge translation and clinical practice in heart failure. This is a prospective observational cohort study of patients with, or at risk for, heart failure. Patients will have sequential testing including quality of life and clinical outcomes over 12 months. After that time, study participants will be passively followed via linkage to external administrative databases. Clinical outcomes of interest include death, hospitalization, emergency department visits, physician resource use and/or heart transplant. Patients will be followed for a total of 5 years.

Discussion: Alberta HEART has the primary objective to define new diagnostic criteria for patients with heart failure with preserved ejection fraction. New criteria will allow for targeted therapies, diagnostic tests and further understanding of the patients, both at-risk for and with heart failure.

Trial registration: ClinicalTrials.gov NCT02052804.

Show MeSH
Related in: MedlinePlus